Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $210 Billion
- Q2 2025
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 25,070 shares of VRDN stock, worth $450,507. This represents 0.17% of its overall portfolio holdings.
Number of Shares
25,070
Previous 25,707
2.48%
Holding current value
$450,507
Previous $347 Million
1.14%
% of portfolio
0.17%
Previous 0.22%
Shares
7 transactions
Others Institutions Holding VRDN
# of Institutions
184Shares Held
82.7MCall Options Held
78.9KPut Options Held
417K-
Deep Track Capital, LP Greenwich, CT5.38MShares$96.7 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$87.6 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$81 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$79.6 Million7.39% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $717M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...